Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1α-mediated mechanism

Biochemical and Biophysical Research Communications

Volumn 391, Issue 2, 2010, Pages 1274-1279

  Pei, Guo Ting ^a   Wu, Chi Wei ^a   Lin, Wan Wan ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

DcR2; Hypoxia; TRAIL; Tumor resistance

Indexed keywords

DECOY RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN; PROTEIN P53; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPOXIA; NULL ALLELE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL HYPOXIA; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; PROMOTER REGIONS, GENETIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 73449110126     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.058     Document Type: Article

References (25)

1. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
2. LeBlanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10 (2003) 66-75
3. Wajant H., Gerspachand J., and Pfizenmaier K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev. 16 (2005) 55-76
4. Degli-Esposti M.A., Smolak P.J., Walczak H., et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186 (1997) 1165-1170
5. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
6. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., and Goodwin R.G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7 (1997) 813-820
7. Marsters S.A., Sheridan J.P., Pitti R.M., et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7 (1997) 1003-1006
8. Papenfuss K., Cordier S.M., and Walczak H. Death receptors as targets for anti-cancer therapy. J. Cell Mol. Med. 12 (2008) 2566-2585
9. Bellail A.C., Qi L., Mulligan P., Chhabra V., and Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials 4 (2009) 34-41
10. Holoch P.A., and Griffith T.S. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur. J. Pharmacol. 625 (2009) 63-72
11. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27 (2008) 6207-6215
12. Gardner L.B., and Corn P.G. Hypoxic regulation of mRNA expression. Cell Cycle 7 (2008) 1916-1924
13. Rademakers S.E., Span P.N., Kaanders J.H., Sweep F.C., van der Kogel A.J., and Bussink J. Molecular aspects of tumour hypoxia. Mol. Oncol. 2 (2008) 41-53
14. Rankin E.B., and Giaccia A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 15 (2008) 678-685
15. Hockel M., and Vaupel P. Biological consequences of tumor hypoxia. Semin. Oncol. 28 (2001) 36-41
16. Yee K.M., Spivak-Kroizman T.R., and Powis G. HIF-1 regulation: not so easy come, easy go. Trends Biochem. Sci. 33 (2008) 526-534
17. Liu X., Yur P., Khuri F.R., and Sun S.Y. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res. 65 (2005) 9169-9175
18. Sheikh M.S., Huang Y., Fernandez-Salas E.A., et al. The antiapoptotic decoy receptor TRID and TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 18 (1999) 4153-4159
19. Bernard D., Quatannens B., Vandenbunder B., and Abbadie C. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J. Biol. Chem. 276 (2001) 27322-27328
20. Ravi R., Bedi G.C., Engstrom L.W., Zeng Q., Mookerjee B., Gelinas C., Fuchs E.J., and Bedi A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat. Cell Biol. 3 (2001) 409-416
21. Yoshida T., Maeda A., Tani N., and Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett. 507 (2001) 381-385
22. Liu X., Yue P., Khuri F.R., and Sun S.Y. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 64 (2004) 5078-5083
23. Moeller B.J., and Dewhirst M.W. HIF-1 and tumour radiosensitivity. Br. J. Cancer 95 (2006) 1-5
24. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
25. Fisher M.J., Virmani A.K., Wu L., et al. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin. Cancer Res. 7 (2001) 1688-1697